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OBJECTIVES: Specific microRNA (miRNA) signatures in biological fluids can facilitate earlier detection of
the tumors being then minimally invasive diagnostic biomarkers. Circulating miRNAs have also
emerged as promising diagnostic biomarkers for colorectal cancer (CRC) screening. In this study, we
investigated the performance of a specific signature of miRNA in plasma samples to design a robust
predictive model that can distinguish healthy individuals from those with CRC or advanced
adenomas (AA) diseases.
METHODS: Case control study of 297 patients from 8 Spanish centers including 100 healthy individuals, 101
diagnosedwith AA, and 96CRC cases. Quantitative real-time reverse transcriptionwas used to quantify
a signature of miRNA (miRNA19a,miRNA19b, miRNA15b,miRNA29a,miRNA335, andmiRNA18a)
in plasma samples. Binary classifiers (Support Vector Machine [SVM] linear, SVM radial, and SVM
polynomial) were built for the best predictive model.
RESULTS: Area under receiving operating characteristic curve of 0.92 (95% confidence interval 0.871–0.962)
was obtained retrieving a model with a sensitivity of 0.85 and specificity of 0.90, positive predictive
value of 0.94, and negative predictive value of 0.76 when advanced neoplasms (CRC and AA) were
compared with healthy individuals.
CONCLUSIONS: We identified and validated a signature of 6 miRNAs (miRNA19a, miRNA19b, miRNA15b,
miRNA29a,miRNA335, andmiRNA18a) as predictors that candifferentiate significantly patientswith
CRC and AA from those who are healthy. However, large-scale validation studies in asymptomatic
screening participants should be conducted.
SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/CTG/A3.
Clinical and Translational Gastroenterology 2019;10:e-00003. https://doi.org/10.14309/ctg.0000000000000003
INTRODUCTION
Colorectal cancer (CRC) is the third most commonly diagnosed
cancer and the fourth leading cause of cancer-related death
worldwide and is expected to increase by 60% by 2030 (1).
Although some strategies are available to screen average
risk patients including fecal occult blood testing (FOBT)
(immunochemical test) alone or combined with stool DNA
examination, endoscopy (sigmoidoscopy or colonoscopy), and
a blood-based test to evaluate biomarkers, each one of them
have important disadvantages (2). Current fecal test has the
advantages of cut-off that can be adjusted and low price whereas
stool DNA test has shown to detect significantly more cancers
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than fecal test and better sensitivity for advanced adenomas
(AA). By contrast, lower specificity demandsmore colonoscopy
resources being invasive and costly. Sigmoidoscopy and colo-
noscopy offer direct visualization and detection of a colonic
polyps or advanced neoplasia with the advantage of getting
a pathology specimen.
Only adequate biomarkers used in a screening setting will
allow detecting precancerous adenomas (called AA) that could be
removed during colonoscopy, reducing cancer incidence or also
detecting malignant lesions at stages where cure is possible. To
achieve higher levels of adherence to CRC screening, accurate
blood-based test seems to be the best strategy (3).
MicroRNAs (miRNAs) are 18–22 nucleotide noncoding
RNAs that post-transcriptionally regulate gene expression and
control various cellularmechanisms including tumorigenesis and
the development of various types of cancers (4–6). Accumulating
evidence supports the existence of specific miRNA in biological
fluids that can facilitate earlier detection of the tumors becoming
then diagnostic biomarkers. In particular, circulating miRNAs
have also emerged as promising diagnostic biomarkers for CRC
(5). For instance, several authors demonstrated that miR21 in
serum is a promising biomarker for the early detection and
prognosis of CRC (7,8). More recently, miR-200c and miR-203
implicated in epithelial-to-mesenchymal transition have been
described as noninvasive biomarker for CRC prognosis and
to predict metastasis (9,10). Fecal miR-106a was shown to be
a useful maker for patients with CRC negative for immuno-
chemical fecal test (11). Because some other publications reported
different accuracy values when various miRNAs are used as
biomarkers, reproducible and confirmatory studies are required
to validate analytical and clinical robustness.
In line with these innovative data, we demonstrated in a pre-
vious study (12) that patients with CRCandAAhave significantly
different patterns of miRNA expression than healthy individuals.
A set of miRNAs (i.e., miRNA19a, miRNA19b, miRNA15b,
miRNA29a, miRNA335, and miRNA18a) is upregulated, having
discriminative capacity when found in plasma samples.
We hypothesized that a specific signature of miRNA could be
used for CRC screening purposes.
Based on our previous work, our aim here was to design and
validate a robust predictive model that can distinguish healthy
individuals from thosewith advanced neoplasm (i.e., CRCorAA)
in a larger cohort to confirm clinical validity.
METHODS
Study subjects
A total of 300 Caucasian subjects from 8 Spanish hospitals were
enrolled for a case–control study (AMD-MCR-2014-01) con-
ducted fromMay 2014 to June 2016. The study was approved by
respective Clinical Research Ethics Committee. All participants
provided written informed consent. The study was designed to
develop and validate a new test for CRC screening after a bio-
marker discovery phase conducted previously in a series of 196
patients (12).
Inclusion criteria included controls, AA and a reduced number
of CRC subjects from a CRC screening program referred to colo-
noscopy after a fecal immunochemical test (FIT) positive result,
and additional clinically diagnosed CRC scheduled for surgery
(majority of CRC cases). Exclusion criteria included patients who
have developed any another type of cancer in the previous 5 years,
thosewhohavepreviously received chemotherapyor radiotherapy,
subjects previously diagnosed with AA, familial adenomatous
polyposis, Lynch syndrome, or inflammatory bowel disease.
Three of the 300 subjects were invalid because they did not
fulfill inclusion criteria due to incorrect age or diagnosed with
a non-AA. Two hundred ninety-seven subjects were finally
valid and included in the study: 100 healthy individuals, 101
patients with AA, and 96 patients with CRC. We considered
AA with a size of at least 10 mm or having a high grade of
dysplasia or $20% villous component. Characteristics of the
patients are shown in Table 1. CRC staging system used was the
American Joint Committee on CancerTumorNodesMetastasis
classification.
Blood collection and plasma isolation
Peripheral blood from participants was drawn before colonoscopy
and before any polyp or cancer resection, the same day of the
procedure. Ten milliliters of blood were collected in a BD Vacu-
tainer blood collection tube (Becton Dickinson, Toronto, Canada)
and kept at room temperature within 12 hours of plasma isolation.
Double centrifugation was required for plasma separation.
RNA isolation
Total RNA including also miRNAs was isolated from 500 mL of
plasma using mirVana PARIS kit (Ambion by Life Technologies,
Carlsbad,CA) and followingmanufacturer’s instructions. Cel-miR-39
was added as exogenous control in all samples. RNAwas eluted in 30
mL of nuclease-free water and kept at280 °C until retrotranscribed.
miRNA expression analysis
Complementary DNA production from RNA was conducted
using TaqMan MicroRNA Assays (Life Technologies). Briefly,
2mLofRNAwere retrotranscribed andpreamplified in singleplex
for 12 cycles with TaqMan PreAmp Master Mix (Life Technol-
ogies). The expression of each one of the targetmiRNAs (miR19a,
miR19b, miR15b, miR29a, miR335, and miR18) (12), the
housekeeping miR-1228, and the spike-in cel-miR-39 was eval-
uated with TaqMan MicroRNA Assays (Life Technologies) by
real-time PCR in a Viia7 Real Time PCR system (Life Technol-
ogies). Both miR-1228 and cel-miR-39 were used for normali-
zation. To calculate miRNA levels, we used cycle number at
threshold (Ct) values from automatic threshold, and PCR was
done in triplicate.
Statistical analysis
Data cleaning (consistency and uniformity). We used the R
language (https://www.R-project.org/; version 3.4.1) and tidy-
verse package (version 1.1.1) for data filtering and normalization.
Starting from rawdata (Ct data in base 2 logarithm), samples with
missing values in at least one miRNA (biomarker or normalizer)
were removed. Also, samples with an outlier value in one of the
miRNAs were removed. Outlier criteria take into account the
different available sample groups (control or healthy, AA, CRC or
both referred as advanced neoplasm); it uses boxplot.stats func-
tion from R (grDevices package). Within each group, it consid-
ered outliers if the values are beyond 61.58 interquartile range/
sqrt(n).
After filtering process, the data were normalized using
a combination of exogenous and endogenous miRNAs: cel-miR-
39 and miR-1228, respectively. For each sample, the formula that
obtains the normalized value is2miRNAx – (cel-miR-391miR-
1228)/2), where miRNAx is the raw value of the specific target
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biomarker to be normalized. Because these raw values are based to
2 logarithms, this normalization is equivalent to geometric mean
of original (exponential) values.
Building a control vs condition classifier. We used the caret
package (version 6.0-78; https://CRAN.R-project.org/pack-
age5caret) from R to build several binary classifiers (Support
Vector Machine [SVM] linear, SVM radial, and SVM poly-
nomial) and validated them using 5-fold cross validation,
repeating 10 times (13). These classifiers were trained to
classify control samples against AA samples or CRC samples
or both (referred as advanced neoplasm samples). Different
combinations of tuning parameter values were tested for each
classifier: (i) Cost (all classifiers), 5 possible values ranging
from 222 to 22; (ii) Sigma (radial), values ranging from 0.04 to
0.7; (iii) Scale; and (iv) Polynomial degree (only for the SVM
polynomial), ranging from 1023 to 1021 (3 values) and 1 to 3,
respectively. Furthermore, 5 different types of preprocessing
were performed: (i) None; (ii) Center and Scale; (iii) BoxCox;
(iv) BoxCox and Center; or (v) BoxCox, Center, and Scale.
Then, for each classification objective (control vs AA, control
Table 1. Clinicopathological characteristics of the patients
Total (n 5 297) Control (n5 100) AA (n5 101) CRC (n 5 96)
Mean age (s.d.) 65.7 (11.5) 60.3 (11.1) 63.4 (9.4) 72.0 (10.1)
Gender
Male 174 51 73 50
Female 123 49 28 46
Colorectal features
TNM pathological stage
I — — — 20
II — — — 23
III — — — 34
IV — — — 14
Unknown — — — 5
Location
Ascending colon and cecum — — — 31
Descending colon and sigma — — — 39
Transverse colon — — — 6
Rectum — — — 20
Proximal/distal
Proximal (cecum, ascending, hepatic
flexure, and transverse colon)
— — — 37
Distal (splenic flexure, descending, and
sigmoid colon)
— — 59
Advanced colorectal adenoma features
Size $ 10 mm — — 93 —
Mean size (mm) (s.d.) — — 20.2 (11.8) —
Small AA (#15 mm) — — 51 —
Big AA (.15 mm) — — 47 —
No. AAs mean (s.d.) — — 3 (3) —
Stage 0 — — 6 —
High-grade dysplasia
Yes — — 38 —
No — — 63 —
Villous component
Yes — — 41 —
No — — 55 —
Unknown — — 5 —
AA, advanced adenomas; CRC, colorectal cancer; TNM, Tumor Nodes Metatastasis classification.
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vs CRC, or control vs advanced neoplasm), a total of 1,925
different models were generated and validated. Statistical
significance was considered when P , 0.05 in two-side
testing.
Area under the curve (AUC) was used as main performance
metric to compare models (calculated with caTools package,
version 1.17.1) (14). Final AUC for one model is calculated as the
average over the 10 iterations of 5-fold cross validations and a cut-
off of 0.5. AUC, sensitivity, and specificity values were evaluated
for the best globalmodel using thewhole set. Themethod used for
calculating confidence intervals (CIs) of AUCs was DeLong
method integrated within the pROC package (15). Partial AUC
when specificity and sensitivity are restricted from 0.80 to 1.00 is
showed in Supplementary Table 1 (Supplemental Digital Content
1, http://links.lww.com/CTG/A3).
We used Brier score for assessing the accuracy of predictions,
applicable where predictions must assign probabilities to a set of
discrete outcomes. It is ameasure of themean squared error of the
probability forecasts and it is expressed as the mean squared
difference between a predicted probability (which must be be-
tween 0 and 1) and the actual outcome (which can take on values
of only 0 and 1). The Brier score ranges from 0 for a perfect
forecast to 1 for the worst possible forecast. The lower the Brier
score is for a set of predictions, the better the predictions are
calibrated (16).
RESULTS
Of the 300 enrolled, 297 were successfully evaluated and 3 were
withdrawn due to lack of inclusion criteria (age and diagnosed
with a non-advanced adenoma). Of these 297, 100 were di-
agnosed by colonoscopy as healthy (controls), 101 with AA, and
96 with CRC after blood sample was taken for the study.
In more detail, we enrolled 174 (58.6%) men and 123 (41.4%)
woman. Most individuals tested fell within the range of 50–80
years old and mean average was 65.7 6 11.5 (Figure 1a).
The AA group included subjects with at least one of the fol-
lowing characteristics: size bigger than 10 mm as reported by
pathological examination, high grade of dysplasia (HGD), and/or
villous component. Mean size of AA was 20.2 mm and the mean
of number of adenomas per subject was 3. The CRC group in-
cluded 20, 23, 34, and 14 subjects diagnosed with stage I, II, III,
and IV, respectively. In 5 cases, the stage was not determined.
With respect to location, 31 cases were located in ascending
colon–cecum; 39 in descending colon–sigma; 6 cases in trans-
verse colon; and 20 cases in rectum. Number of adenomas and
size (cm) were represented as bar graph to show patients’ distri-
bution (Figures 1b,c). Distribution of CRC stageswere also shown
in Figure 1d.
Median age for control group (healthy individuals) was 60.3
years, 63.4 for AA, and 72.0 for CRC (Table 1). As a case–control
study, CRC is more frequent in elderly population. Starting from
Figure 1. Clinicopathological features of patients. (a) Age distribution of the whole cohort of patients (N5 297 individuals). (b) Distribution of patients with
AA.Number of adenomas are represented (N5101 individuals). (c) Distribution of advancedadenomasize (cm) (N5101 individuals). (d) Representation
of patients with CRC depending on tumor stage. AA, advanced adenoma; CRC, colorectal cancer.
Herreros-Villanueva et al.4
C
O
LO
N
Clinical and Translational Gastroenterology VOLUME 10 | JANUARY 2019 www.clintranslgastro.com
raw data (Ct data in base 2 logarithm), 29 samples with missing
values in at least one miRNA (biomarker or normalizer) were
removed. Also, 47 samples with an outlier value in one of the
miRNAs were removed.
When analyzing control vs advanced neoplasm (including
patients with CRC and AA), performance of the model without
cross-validation gave us an AUC 5 0.92 (95% CI 0.871–0.962)
with a sensitivity of 0.85 and specificity of 0.90 and positive
predictive value (PPV) 5 0.94 and negative predictive value
(NPV) 5 0.76 (Figure 2a and Table 2). According to our calcu-
lations, the cohort of patients reaches the best prediction model
with an AUC of 0.79 (95% CI 0.723–0.841) after a cross-
validation process, using an SVM-based model with a radial
kernel and a Cost 5 0.50 and Sigma 5 0.44 (see Supplementary
Figure 1, Supplemental Digital Content, http://links.lww.com/
CTG/A3). For additional sensitivities and specificities, data are
shown in Supplementary Table 2 (Supplemental Digital Content
1, http://links.lww.com/CTG/A3).
When analyzing control vs CRC, an AUC 5 0.95 (95% CI
0.903–0.991) with a sensitivity of 0.91 and specificity of 0.90, and
PPV5 0.81 andNPV5 0.95was obtained.Moreover, anAUC5
0.91 (95%CI 0.868–0.959)with a sensitivity of 0.95 and specificity
of 0.90, and PPV5 0.82 and NPV5 0.97 was observed for AA vs
control (Figure 2b,c and Table 2). Assuming a hypothetical
screening population in which expected prevalence of CRC and
AA were 1:100 and 7:100, respectively, PPV5 0.08 and NPV5
0.99would be obtained forCRC andPPV5 0.42 andNPV5 0.99
for AA.
Figure 3 shows a model based on Brier score representing the
probabilistic prediction of samples as healthy or advanced neo-
plasm (i.e., CRC or AA). A Brier score of 0.116 demonstrates
a very good prediction forecast in separation between samples
from patients (CRC and AA) and healthy.
Sensitivity did not vary significantly according to cancer stage
or location within the colon. In fact, sensitivity of 6 miRNA sig-
natures was 0.94 and specificity of 0.87 for early stages (including
stages I and II), whereas it was 0.94 and 0.86, respectively, for late
stages (III and IV). Likewise, sensitivity/specificity was 0.88/0.94
for proximal CRC and 0.89/0.94 for distal CRC (Figure 4 and
Table 3).
Individual evaluation of miRNAs analyzed, miRNA15b and
miRNA29a are consistently showing its high significance when
contributing to distinguish control vs advanced neoplasm group.
In this cohort of patients, miRNA15b, miRNA29a, and
miRNA335 analyzed independently showed statistically signifi-
cant P values as obtained by means t test (7.9e-5, 5.7e-5, and
0.013, respectively). This was observed in univariate, logistic re-
gression models and also SVM models.
DISCUSSION
CRC is an ideal target for population screening because it is
a prevalent disease in which detection and treatment at an
asymptomatic stage lead to a mortality reduction as it has been
demonstrated in different screening strategies.
Several randomized controlled trials demonstrated that
screening with guaiac FOBT and flexible sigmoidoscopy are ef-
fective in reducing CRC mortality by approximately 16%–25%
(17) and 26%–38 % (18–20), respectively, and even stronger
reductions in incidence and mortality are expected for FIT and
colonoscopy screening due to higher diagnostic accuracy.
Table 2. AUC, sensitivity, specificity, PPV, and NPV between
different combinations for the analyzed cohort
Advanced
neoplasm vs Co CRC vs Co AA vs Co
AUC 0.92 0.95 0.92
Sensitivity 0.85 0.91 0.95
Specificity 0.90 0.90 0.90
PPV 0.94 0.81 0.82
NPV 0.76 0.95 0.97
AA, advanced adenomas; AUC, area under the curve; Co, control; CRC,
colorectal cancer; NPV, negative predictive value; PPV, positive predictive
value.
Advanced neoplasm: includes CRC and AA.
Figure 2. Receiver operating characteristic curve analysis for the 6 microRNA signatures. (a) The model control vs advanced neoplasm; (b) the model
control vs CRC; and (c) the model control vs AA. AA, advanced adenoma; AUC, area under the curve, CRC, colorectal cancer.
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Consequently, with time, big health care organizations have
been changing recommendations. While in 2008, US Preventive
Services Task Force included only 3 strategies: FOBT, flexible sig-
moidoscopy, and colonoscopy, and in 2016, the number of rec-
ommendations was updated to 7 also including FIT-DNA. The
largest study assessing sensitivity and specificity of FIT-DNA test
called Cologuard from Exact Sciences (Madison, WI) demon-
strated a sensitivity of 92% for CRC and 42% for AA at a specificity
of 87%using colonoscopy as gold standard (21).Moreover, in2016,
the Food andDrug Administration approved a blood test to detect
circulating methylated SEPT9 DNA (https://www.accessdata.fda.
gov/cdrh_docs/pdf13/p130001c.pdf) with a low sensitivity (48%)
for detecting CRC (22). FIT characteristics vary between different
studies although meta-analysis estimates an overall cancer sensi-
tivity and specificity of 79% and 94% but FIT lacks the capacity to
detect AA (23). Recent publications comparing diagnostic per-
formance between various quantitative FITs concluded that small
differences in results can be overcome by appropriate threshold
adjustments to yield a desired level of specificity (24,25).
Early detection of AA remains an unmet need as there is no
marketed test available with promising sensitivity for these
lesions becoming cancerous.
The development of more sensitive and specific tests to de-
tect CRC and AA is a reality. The need to increase the adenoma
detection rate for CRC screening is patented in devices that
mechanically or optically try to improve conventional colono-
scopy. Blood-based test may offer advantages compared to
colonoscopy, because it does not require intensive time com-
mitment (bowel preparation, procedure itself, and recovery),
and FIT, as the person should not need to handle their feces at
home with logistic difficulties. It is well known that minimally
invasive tests will achieve higher adherence over time taking
into consideration availability, costs, and patient–clinicians
preferences (26,27).
Figure 3. Classification by probability using Brier score measuring the accuracy of probabilistic predictions ranking from 0 (total accuracy) to 1 (wholly
inaccurate). The lower the Brier score is for a set of predictions, the better the predictions are calibrated.
Figure 4. Receiver operating characteristic curve analysis for the CRC patients. (a) Early stages (I/II) vs Late stages (III/IV). (b) Proximal vs distal location.
CRC, colorectal cancer.
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In this study, we validated a signature of 6 miRNAs as bio-
markers for early detection of CRC in plasma samples from
a cohort of patients with CRC and AA, and healthy individuals.
Our results demonstrated a high sensitivity and specificity using
real-time PCR technology, an easy technique to be performed in
hospitals and diagnostic laboratories. The signature includes
miRNAs previously described and related to CRC development
by other authors (12). Improving sensitivity and specificity is
highly desirable for efficient population-based screening with
good adherence rates. Very promisingly, the signature is able to
detect AA with high sensitivity and specificity.
Herein, a recent publication gave insights about miRNA19a
promoting CRC development when bound directly to the 39-
untranslated region of TIA1 mRNA promoting cell proliferation
and migration of CRC cells (28). Huang et al. (29) also showed
thatmiRNA19a plays an important role inmediating epithelial to
mesenchymal transition andmetastatic behavior in CRC, serving
as a potential marker of lymph node metastasis. Similarly,
miRNA19b-3p promotes colon cancer proliferation and che-
moresistance to oxaliplatin by targeting SMAD4 (30). On the
other hand, experiments from some authors demonstrated that
transcriptional repression of miRNA15b-5p by SIRT1 could
suppress CRC metastasis showing a roll of this miRNA as po-
tential target for therapy (31). Very importantly, Tang et al.
concluded that an increased expression of miRNA29a targets
KLF4, which highlights the potential of miRNA29a inhibitors as
novel agents against CRCmetastasis (32). In fact, data obtained in
our cohort of 297 individuals concluded that miRNA15b and
miRNA29a are significantly contributing to the predictive model
through an overexpression in patients withAAorCRC compared
to those who are healthy.
The proposedmiRNA signature here presented is based on the
combination of several of these miRNAs, some of them pre-
viously associated to colon cancer diagnosis (12), prognosis, or
prediction to response to therapy. Molecular mechanisms clari-
fying how these miRNAs are acting as oncomiRNA must be
elucidated.
With the proposed model integrating values from these spe-
cific miRNAs, the signature possesses a sensitivity of 91% and
specificity of 90% forCRC and sensitivity of 95%and specificity 90%
for AA. According to these values, we present a high-performance
blood-based test. Main advantages of this test are a minimally in-
vasive test for CRC screening and outstanding sensitivity and
specificity for AA.
Sensitivity and specificity in detecting proximal and distal
advanced neoplasia are similar for our miRNA signature. In view
of the findings of the current results, this miRNA signature faces
the raising burden of proximal colon cancer. Very importantly,
detection rate forCRC in early stages (I and II) is comparablewith
late (III and IV). Both characteristics offer a superiority to FIT.
Although some authors demonstrated a better diagnostic
performance for the relative detection of CRC in the distal colon
than that in the proximal colon when using fecal test (33), other
showed that FIT is equally sensitive for proximal and distal
neoplasia (34). Niedermaier et al. (23) conducted a systematic
review and meta-analysis of 10 studies (23,34–41) performed in
screening populationwith the aim to evaluate performance of FIT
depending on stratified by left or right side where advanced
neoplasia was located. This meta-analysis estimated a FIT sen-
sitivity for CRC and AA detection of 63% and 22% in the right
colon and 67% and 32% in the left colon and rectum, concluding
that there are small differences in CRCdetection and pronounced
differences in AA detection between left- and right-sided
neoplasia.
In the work we presented in this manuscript, using a miRNA
signature, we demonstrated equally effectiveness to detect lesions
in both locations proximal and distal.
We consider that high sensitivity is the most important at-
tribute for cancer screening test but high specificity is also im-
portant, as otherwise it could affect participants obtaining false
positive results when in fact they are healthy, due to low preva-
lence of CRC, which ultimately will increase anxiety in patients
while increasing costs in unnecessary colonoscopies. The per-
centage of US residents up-to-date on CRC screening has not
increased appreciably since 2010 and remains at approximately
62.4% in 2015 (42). The National Colorectal Cancer Roundtable
has established a goal of 80% adherence on CRC screening by the
year 2018.
Very interestingly, this miRNA signature is able to detect
cancers occurring at the right side, which is an advantage because
incidence of right-sided colon cancers has been progressively
increasing over recent decades (43). Colonoscopy is more effec-
tive in preventing left-sided as compared with right-sided and
blood-based tests could represent a solution in early detection for
a demonstrated poorer prognosis and worse response to targeted
therapy of right-sided cancers (44).
The COLONPREV study, a randomized, controlled trial,
demonstrated that patients are more likely to participate in
screening programs using a noninvasive test as FIT compared to
those choosing colonoscopy (45). Importantly, on screening ex-
amination, the number of subjects in whom CRC was detected
was similar by the 2 methodologies although more adenomas
were identified in the colonoscopy group. The result of the
COLONPREV trial suggested that innovative noninvasive or
minimally invasive methods are required for AA detection. Our
miRNA signature evidenced a robust method for AA detection in
plasma samples.
Here we presented a validated model in which a miRNA sig-
nature could be integrated in a minimally invasive method for
CRC screening purposes after further prospective clinical vali-
dation. One of themain factors for success in screening programs
and reducing CRC mortality is to achieve a high participation.
Table 3. AUC, sensitivity, specificity, PPV, andNPV are shown for
colorectal cancer cases
Stage I/II Stage III/IV Proximal Distal
AUC 0.95 0.96 0.97 0.95
Sensitivity 0.94 0.94 0.88 0.89
Specificity 0.87 0.86 0.94 0.94
PPV 0.94 0.94 0.81 0.89
NPV 0.87 0.86 0.96 0.94
Early stages are stage I/II and lately stages as stage III/IV. Localization of the
tumors are classified as proximal (includes the cecum, the ascending
colon—the right side of the colon, and the transverse colon) or distal
(descending colon—left side of the colon and the sigmoid colon—the S-shaped
section of the colon that connects to the rectum).
AUC, area under the curve; NPV, negative predictive value; PPV, positive
predictive value.
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Further studies in a real CRC screening population are required to
validate the model presented in this article. Additionally, a com-
parison or even combination with FIT screening method will be
of great value. Moreover, prospective studies will help to gain
evidence about appropriate follow-up of positiveness of blood-
based test although diagnostic colonoscopy is negative.
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